Evaluating the Translational Potential of Bacteriocins as an Alternative Treatment for Staphylococcus aureus Infections in Animals and Humans

BACTERIOCIN AP7121 AS A POTENTIAL TREATMENT FOR SURGICAL SITE INFECTIONS BY Staphylococcus aureus: in vitro/in vivo MODELS

Surgical site infections (SSIs) are among the leading healthcare-associated infections worldwide, and S. aureus is the most prevalent cause. Antimicrobial resistance, dormant cells, and biofilm formation contribute to treatment failure in SSIs. Therefore, new therapeutic approaches are needed to fight SSIs. The bacteriocin AP7121 has previously shown in vitro bactericidal and anti-biofilm activity against multi-resistant S. aureus. This study aimed to advance on the characterization of the in vitro activity of AP7121 against dormant forms of methicillin-resistant S. aureus (MRSA) and its effect on the adherence of a biofilm-producing strain to sutures. Additionally, a preliminary murine model of SSIs was utilized to proceed toward the in vivo application of AP7121, comparing its antimicrobial potency with the commercial antibiotic Cefazolin. Initially, MRSA cultures were grown to the logarithmic growth phase and subsequently exposed to varying concentrations of AP7121. Viable bacterial counts were assessed at different times of incubation. AP7121 demonstrated a concentration-dependent effect on dormant cells of MRSA when using 8xMIC. The effect of AP7121 on the adherence of biofilm-producing S. aureus to suture surfaces was subsequently evaluated using scanning electron microscopy. AP7121 showed significant inhibitory effects on the adherence of S. aureus in suture threads. Finally, AP7121 demonstrated a significant in vivo bactericidal effect against S. aureus in SSI model. The reduction in viable bacterial counts compared to the control group exceeded 90% for both Cefazolin and AP7121 treatments. These preliminary findings highlight AP7121 as a novel and promising antimicrobial peptide for potential applications in human and veterinary medicine.

The potential of Streptococcus pyogenes and Escherichia coli bacteriocins in synergistic control of Staphylococcus aureus

Staphylococcus aureus has developed resistance to most conventional antibiotics and is a causative agent of serious infections. Alternative therapies are urgently needed. Bacteriocins are ribosomally synthesized antimicrobial peptides produced by bacteria, including Escherichia coli (E. coli) and Streptococcus pyogenes (S. pyogenes), and represent a potential solution. While several bacteriocins have shown promise, their synergy with bacteriocins from other bacterial species remains largely unexplored. This work used agar diffusion on Muller-Hinton Agar (MHA) with S. aureus as a test bacterium to evaluate E. coli, S. pyogenes and their combined bacteriocins. The bacteriocins of S. pyogenes showed the maximum antimicrobial activity of zone of inhibition (ZOI), 24.93 mm, compared to that of E. coli bacteriocin, which was 19.28 mm, and that of the combined ones at 100% concentration, 22.6 mm. The combined bacteriocins at 50% concentration showed a reduced activity of 18.35 mm. These observations suggest that the bacteriocins produced by S. pyogenes have higher specificity and activity against S. aureus, making them effective therapeutic agents in the fight against multidrug-resistant infections.

Pharmacological composition based on bacteriocinnisin in experiments in vitro and in vivo

Background

Antibiotic resistance is a global health problem related to the transmission of bacteria and genes between humans and animals. The development of new drugs with antimicrobial activity research is an urgent task of modern science.

Aim

The article presents data of in vitro and in vivo experiments on new pharmaceutical composition based on nisin.

Methods

The antimicrobial activity was studied on the mastitis pathogens. To identify microorganisms the Matrix-Assisted Lazer Desorption/Ionization Time-of-Flight (MALDI-TOF) (mass spectrometry) method was performed using. To determine sensitivity, the serial dilution method and the diffusion method were used. On laboratory animals, biochemical, hematological, and histological research methods were used. Female nonlinear white laboratory rats were used, which were divided into one control group and three experimental ones.

Results

"Duration" factor was statistically significant for the following indicators: hemoglobin, hematocrit, leukocytes, lymphocytes, erythrocyte sedimentation rate, and eosinophils. The "Dose" factor did not show significance for any indicator, which means that the effect was similar regardless of the dose chosen. When analyzing the biochemical indicators, significant differences were found in the "Duration" and "Dose" factors, in the direction of a decrease in the indicators of total protein, globulins, urea, and an increase in the concentration of alkaline phosphatase. When conducting histological studies in the first experimental group, it was established that there were no changes in the structural and functional units of the organs. In animals of the second experimental group, the presence of reversible pathological processes of a compensatory nature was noted. More profound changes in the structure of the studied organs were recorded in the third experimental group.

Conclusion

An in vitro study on cell cultures showed that the pharmacological composition has high antimicrobial activity against isolates from the mammary gland secretion of cows with mastitis. An in vivo study on laboratory animals showed that the developed composition belongs to the IV class of substances "low-hazard substances". Histological examination made it possible to select the safest dose of the pharmacological composition of no more than 500 mg/kg.

Natural products from the human microbiome: an emergent frontier in organic synthesis and drug discovery

Often referred to as the "second genome", the human microbiome is at the epicenter of complex inter-habitat biochemical networks like the "gut-brain axis", which has emerged as a significant determinant of cognition, overall health and well-being, as well as resistance to antibiotics and susceptibility to diseases. As part of a broader understanding of the nexus between the human microbiome, diseases and microbial interactions, whether encoded secondary metabolites (natural products) play crucial signalling roles has been the subject of intense scrutiny in the recent past. A major focus of these activities involves harvesting the genomic potential of the human microbiome via bioinformatics guided genome mining and culturomics. Through these efforts, an impressive number of structurally intriguing antibiotics, with enhanced chemical diversity vis-à-vis conventional antibiotics have been isolated from human commensal bacteria, thereby generating considerable interest in their total synthesis and expanding their therapeutic space for drug discovery. These developments augur well for the discovery of new drugs and antibiotics, particularly in the context of challenges posed by mycobacterial resistance and emerging new diseases. The current landscape of various synthetic campaigns and drug discovery initiatives on antibacterial natural products from the human microbiome is captured in this review with an intent to stimulate further activities in this interdisciplinary arena among the new generation.

Bacteriocins: potentials and prospects in health and agrifood systems

Bacteriocins are highly diverse, abundant, and heterogeneous antimicrobial peptides that are ribosomally synthesized by bacteria and archaea. Since their discovery about a century ago, there has been a growing interest in bacteriocin research and applications. This is mainly due to their high antimicrobial properties, narrow or broad spectrum of activity, specificity, low cytotoxicity, and stability. Though initially used to improve food quality and safety, bacteriocins are now globally exploited for innovative applications in human, animal, and food systems as sustainable alternatives to antibiotics. Bacteriocins have the potential to beneficially modulate microbiota, providing viable microbiome-based solutions for the treatment, management, and non-invasive bio-diagnosis of infectious and non-infectious diseases. The use of bacteriocins holds great promise in the modulation of food microbiomes, antimicrobial food packaging, bio-sanitizers and antibiofilm, pre/post-harvest biocontrol, functional food, growth promotion, and sustainable aquaculture. This can undoubtedly improve food security, safety, and quality globally. This review highlights the current trends in bacteriocin research, especially the increasing research outputs and funding, which we believe may proportionate the soaring global interest in bacteriocins. The use of cutting-edge technologies, such as bioengineering, can further enhance the exploitation of bacteriocins for innovative applications in human, animal, and food systems.

The role of proteinaceous toxins secreted by Staphylococcus aureus in interbacterial competition

Staphylococcus aureus is highly adapted to colonization of the mammalian host. In humans the primary site of colonization is the epithelium of the nasal cavity. A major barrier to colonization is the resident microbiota, which have mechanisms to exclude S. aureus. As such, S. aureus has evolved mechanisms to compete with other bacteria, one of which is through secretion of proteinaceous toxins. S. aureus strains collectively produce a number of well-characterized Class I, II, and IV bacteriocins as well as several bacteriocin-like substances, about which less is known. These bacteriocins have potent antibacterial activity against several Gram-positive organisms, with some also active against Gram-negative species. S. aureus bacteriocins characterized to date are sporadically produced, and often encoded on plasmids. More recently the type VII secretion system (T7SS) of S. aureus has also been shown to play a role in interbacterial competition. The T7SS is encoded by all S. aureus isolates and so may represent a more widespread mechanism of competition used by this species. T7SS antagonism is mediated by the secretion of large protein toxins, three of which have been characterized to date: a nuclease toxin, EsaD; a membrane depolarizing toxin, TspA; and a phospholipase toxin, TslA. Further study is required to decipher the role that these different types of secreted toxins play in interbacterial competition and colonization of the host.